Sector Gamma AS decreased its stake in shares of Spark Therapeutics (NASDAQ:ONCE) by 11.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 46,600 shares of the biotechnology company’s stock after selling 5,900 shares during the period. Spark Therapeutics accounts for 0.6% of Sector Gamma AS’s portfolio, making the stock its 29th largest position. Sector Gamma AS owned about 0.13% of Spark Therapeutics worth $3,103,000 as of its most recent filing with the SEC.
Other hedge funds also recently modified their holdings of the company. Public Employees Retirement Association of Colorado acquired a new position in Spark Therapeutics during the fourth quarter worth approximately $163,000. Centaurus Financial Inc. acquired a new position in Spark Therapeutics during the first quarter worth approximately $256,000. Aperio Group LLC increased its position in Spark Therapeutics by 29.2% during the fourth quarter. Aperio Group LLC now owns 3,972 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 898 shares during the last quarter. NJ State Employees Deferred Compensation Plan acquired a new position in Spark Therapeutics during the first quarter worth approximately $266,000. Finally, Xact Kapitalforvaltning AB acquired a new position in Spark Therapeutics during the fourth quarter worth approximately $208,000. 99.99% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts recently commented on the stock. Wedbush reaffirmed an “underperform” rating and set a $40.00 price target on shares of Spark Therapeutics in a research report on Wednesday, May 9th. BMO Capital Markets set a $78.00 price objective on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, May 9th. Stifel Nicolaus boosted their price objective on shares of Spark Therapeutics from $64.00 to $76.00 and gave the stock a “buy” rating in a research note on Wednesday, May 9th. Royal Bank of Canada boosted their price objective on shares of Spark Therapeutics to $75.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 9th. Finally, Barclays reiterated an “overweight” rating and set a $85.00 price objective (up from $64.00) on shares of Spark Therapeutics in a research note on Wednesday, May 9th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $76.10.
Shares of Spark Therapeutics opened at $77.53 on Thursday, Marketbeat Ratings reports. Spark Therapeutics has a twelve month low of $75.42 and a twelve month high of $77.96.
Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Tuesday, May 8th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.80). The firm had revenue of $15.68 million during the quarter, compared to analysts’ expectations of $51.55 million. Spark Therapeutics had a negative net margin of 935.38% and a negative return on equity of 51.76%. Spark Therapeutics’s revenue for the quarter was up 1134.6% compared to the same quarter last year. During the same quarter last year, the company posted ($1.70) earnings per share. sell-side analysts forecast that Spark Therapeutics will post -3.47 EPS for the current fiscal year.
In other news, COO John Furey sold 20,000 shares of the company’s stock in a transaction on Thursday, April 12th. The shares were sold at an average price of $77.51, for a total value of $1,550,200.00. Following the completion of the transaction, the chief operating officer now directly owns 20,000 shares in the company, valued at $1,550,200. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 40,000 shares of company stock valued at $3,200,466 over the last 90 days. Insiders own 5.90% of the company’s stock.
Spark Therapeutics Profile
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.
Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics (NASDAQ:ONCE).
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.